Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Status of group B streptococcal vaccine development

  • Lin, Shun Mei (Research Division for Biotechnology, Korea Atomic Energy Research Institute) ;
  • Zhi, Yong (Research Division for Biotechnology, Korea Atomic Energy Research Institute) ;
  • Ahn, Ki Bum (Research Division for Biotechnology, Korea Atomic Energy Research Institute) ;
  • Lim, Sangyong (Research Division for Biotechnology, Korea Atomic Energy Research Institute) ;
  • Seo, Ho Seong (Research Division for Biotechnology, Korea Atomic Energy Research Institute)
  • Received : 2017.12.29
  • Accepted : 2018.01.14
  • Published : 2018.01.31
⟨ Previous Next ⟩

Abstract

Streptococcus agalactiae (group B streptococcus, GBS) is a leading causal organism of neonatal invasive diseases and severe infections in the elderly. Despite significant advances in the diagnosis and treatment of GBS infections and improvement in personal hygiene standards, this pathogen is still a global health concern. Thus, an effective vaccine against GBS would augment existing strategies to substantially decrease GBS infection. In 2014, World Health Organization convened the first meeting for consultation on GBS vaccine development, focusing on the GBS maternal immunization program, which was aimed at reducing infections in neonates and young infants worldwide. Here, we review the history of GBS infections, the current vaccine candidates, and the current status of immunogenicity assays used to evaluate the clinical efficacy of GBS vaccines.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea

References

  1. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 1998;11:497-513.
  2. Doran KS, Nizet V. Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy. Mol Microbiol 2004;54:23-31. https://doi.org/10.1111/j.1365-2958.2004.04266.x
  3. Hansen SM, Uldbjerg N, Kilian M, Sorensen UB. Dynamics of Streptococcus agalactiae colonization in women during and after pregnancy and in their infants. J Clin Microbiol 2004;42:83-9. https://doi.org/10.1128/JCM.42.1.83-89.2004
  4. Fry RM. Prevention and control of puerperal sepsis: bacteriological aspects. Br Med J 1938;2:340-2. https://doi.org/10.1136/bmj.2.4049.340
  5. Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. J Pediatr 1973; 82:707-18. https://doi.org/10.1016/S0022-3476(73)80604-3
  6. Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr 1973;82:724-9. https://doi.org/10.1016/S0022-3476(73)80606-7
  7. Barton LL, Feigin RD, Lins R. Group B beta hemolytic streptococcal meningitis in infants. J Pediatr 1973;82:719-23. https://doi.org/10.1016/S0022-3476(73)80605-5
  8. Fluegge K, Siedler A, Heinrich B, et al. Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 2006;117:e1139-45. https://doi.org/10.1542/peds.2005-2481
  9. Kalliola S, Vuopio-Varkila J, Takala AK, Eskola J. Neonatal group B streptococcal disease in Finland: a ten-year nationwide study. Pediatr Infect Dis J 1999;18:806-10. https://doi.org/10.1097/00006454-199909000-00012
  10. Neto MT. Group B streptococcal disease in Portuguese infants younger than 90 days. Arch Dis Child Fetal Neonatal Ed 2008;93:F90-3.
  11. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm Rep 2010;59:1-36.
  12. Heath PT. Status of vaccine research and development of vaccines for GBS. Vaccine 2016;34:2876-9. https://doi.org/10.1016/j.vaccine.2015.12.072
  13. Schuchat A. Group B streptococcus. Lancet 1999;353:51-6. https://doi.org/10.1016/S0140-6736(98)07128-1
  14. Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009;49:85-92. https://doi.org/10.1086/599369
  15. Paoletti LC, Kasper DL. Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther 2003;3:975-84. https://doi.org/10.1517/14712598.3.6.975
  16. Chaffin DO, Mentele LM, Rubens CE. Sialylation of group B streptococcal capsular polysaccharide is mediated by cpsK and is required for optimal capsule polymerization and expression. J Bacteriol 2005;187:4615-26. https://doi.org/10.1128/JB.187.13.4615-4626.2005
  17. Aoyagi Y, Adderson EE, Min JG, et al. Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci. J Immunol 2005;174:418-25. https://doi.org/10.4049/jimmunol.174.1.418
  18. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol 2014;14:653-66. https://doi.org/10.1038/nri3737
  19. Madrid L, Seale AC, Kohli-Lynch M, et al. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis 2017; 65(Suppl 2):S160-72. https://doi.org/10.1093/cid/cix656
  20. Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS; WHO Product Development for Vaccines Advisory Committee; WHO Product Development for Vaccines Product Development committee. Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. Vaccine 2016;34:2865-9. https://doi.org/10.1016/j.vaccine.2016.02.078
  21. Chen VL, Avci FY, Kasper DL. A maternal vaccine against group B streptococcus: past, present, and future. Vaccine 2013;31 Suppl 4:D13-9. https://doi.org/10.1016/j.vaccine.2012.12.080
  22. Leroux-Roels G, Maes C, Willekens J, et al. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent group B streptococcus vaccine for use in non-pregnant and pregnant women. Vaccine 2016;34:1786-91. https://doi.org/10.1016/j.vaccine.2016.02.044
  23. Madhi SA, Koen A, Cutland CL, et al. Antibody kinetics and response to routine vaccinations in infants born to women who received an investigational trivalent group B streptococcus polysaccharide CRM197-conjugate vaccine during pregnancy. Clin Infect Dis 2017;65:1897-904. https://doi.org/10.1093/cid/cix666
  24. Muller-Graf CD, Whatmore AM, King SJ, et al. Population biology of Streptococcus pneumoniae isolated from oropharyngeal carriage and invasive disease. Microbiology 1999;145(Pt 11):3283-93. https://doi.org/10.1099/00221287-145-11-3283
  25. Teatero S, Ferrieri P, Martin I, Demczuk W, McGeer A, Fittipaldi N. Serotype distribution, population structure, and antimicrobial resistance of group B streptococcus strains recovered from colonized pregnant women. J Clin Microbiol 2017;55:412-22. https://doi.org/10.1128/JCM.01615-16
  26. Flores AR, Galloway-Pena J, Sahasrabhojane P, et al. Sequence type 1 group B streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes. Proc Natl Acad Sci U S A 2015;112:6431-6. https://doi.org/10.1073/pnas.1504725112
  27. Bellais S, Six A, Fouet A, et al. Capsular switching in group B streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development. J Infect Dis 2012;206:1745-52. https://doi.org/10.1093/infdis/jis605
  28. Toyofuku M, Morozumi M, Hida M, et al. Effects of intrapartum antibiotic prophylaxis on neonatal acquisition of group B streptococci. J Pediatr 2017;190:169-73.e1. https://doi.org/10.1016/j.jpeds.2017.07.039
  29. Edwards MS, Rench MA, Rinaudo CD, et al. Immune responses to invasive group B streptococcal disease in adults. Emerg Infect Dis 2016;22:1877-83. https://doi.org/10.3201/eid2211.160914
  30. Alhhazmi A, Hurteau D, Tyrrell GJ. Epidemiology of invasive group B streptococcal disease in Alberta, Canada, from 2003 to 2013. J Clin Microbiol 2016;54:1774-81. https://doi.org/10.1128/JCM.00355-16
  31. Slotved HC, Kong F, Lambertsen L, Sauer S, Gilbert GL. Serotype IX, a proposed new Streptococcus agalactiae serotype. J Clin Microbiol 2007;45:2929-36. https://doi.org/10.1128/JCM.00117-07
  32. Nuccitelli A, Rinaudo CD, Maione D. Group B streptococcus vaccine: state of the art. Ther Adv Vaccines 2015;3:76-90. https://doi.org/10.1177/2051013615579869
  33. Nuccitelli A, Cozzi R, Gourlay LJ, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against group B streptococcus infections. Proc Natl Acad Sci U S A 2011;108:10278-83. https://doi.org/10.1073/pnas.1106590108
  34. Johri AK, Paoletti LC, Glaser P, et al. Group B streptococcus: global incidence and vaccine development. Nat Rev Microbiol 2006;4:932-42. https://doi.org/10.1038/nrmicro1552
  35. Areschoug T, Stalhammar-Carlemalm M, Larsson C, Lindahl G. Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V. Infect Immun 1999;67:6350-7.
  36. Minervax [Internet]. Copenhagen: Minervax; 2017. Available from: http://minervax.com/news/2017/1/5/minervax-announces-positive-data-from-phase-i-clinical-trial.html.
  37. Lin SM, Jang AY, Zhi Y, et al. Vaccination with a latch peptide provides serotype-independent protection against group B streptococcus infection in mice. J Infect Dis 2017; 217:93-102.
  38. Baker JA, Lewis EL, Byland LM, Bonakdar M, Randis TM, Ratner AJ. Mucosal vaccination promotes clearance of Streptococcus agalactiae vaginal colonization. Vaccine 2017;35:1273-80. https://doi.org/10.1016/j.vaccine.2017.01.029
  39. Gourlay LJ, Santi I, Pezzicoli A, Grandi G, Soriani M, Bolognesi M. Group B streptococcus pullulanase crystal structures in the context of a novel strategy for vaccine development. J Bacteriol 2009;191:3544-52. https://doi.org/10.1128/JB.01755-08
  40. Doro F, Liberatori S, Rodriguez-Ortega MJ, et al. Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for group B streptococcus hypervirulent strain COH1. Mol Cell Proteomics 2009;8: 1728-37. https://doi.org/10.1074/mcp.M800486-MCP200
  41. Rioux S, Martin D, Ackermann HW, Dumont J, Hamel J, Brodeur BR. Localization of surface immunogenic protein on group B streptococcus. Infect Immun 2001;69:5162-5. https://doi.org/10.1128/IAI.69.8.5162-5165.2001
  42. Manning SD, Ki M, Marrs CF, et al. The frequency of genes encoding three putative group B streptococcal virulence factors among invasive and colonizing isolates. BMC Infect Dis 2006;6:116. https://doi.org/10.1186/1471-2334-6-116
  43. Zhao Z, Kong F, Gilbert GL. Reverse line blot assay for direct identification of seven Streptococcus agalactiae major surface protein antigen genes. Clin Vaccine Immunol 2006;13:145-9. https://doi.org/10.1128/CVI.13.1.145-149.2006
  44. Kong F, Gowan S, Martin D, James G, Gilbert GL. Molecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes. J Clin Microbiol 2002;40:620-6. https://doi.org/10.1128/JCM.40.2.620-626.2002
  45. Lachenauer CS, Creti R, Michel JL, Madoff LC. Mosaicism in the alpha-like protein genes of group B streptococci. Proc Natl Acad Sci U S A 2000;97:9630-5. https://doi.org/10.1073/pnas.97.17.9630
  46. Larsson C, Stalhammar-Carlemalm M, Lindahl G. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. Vaccine 1999;17:454-8. https://doi.org/10.1016/S0264-410X(98)00218-7
  47. Larsson C, Stalhammar-Carlemalm M, Lindahl G. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infect Immun 1996; 64:3518-23.
  48. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976;294:753-6. https://doi.org/10.1056/NEJM197604012941404
  49. Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004;190:928-34. https://doi.org/10.1086/422756
  50. Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 2014;209:781-8. https://doi.org/10.1093/infdis/jit549
  51. Klegerman ME, Boyer KM, Papierniak CK, Gotoff SP. Estimation of the protective level of human IgG antibody to the type-specific polysaccharide of group B streptococcus type Ia. J Infect Dis 1983;148:648-55. https://doi.org/10.1093/infdis/148.4.648
  52. Guttormsen HK, Baker CJ, Edwards MS, Paoletti LC, Kasper DL. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis 1996; 173:142-50. https://doi.org/10.1093/infdis/173.1.142
  53. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006;13:1004-9. https://doi.org/10.1128/CVI.00112-06
  54. Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol 2012;19:835-41. https://doi.org/10.1128/CVI.00086-12
  55. Choi MJ, Noh JY, Cheong HJ, et al. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B streptococcus. Hum Vaccin Immunother 2018;14:67-73. https://doi.org/10.1080/21645515.2017.1377379
  56. Seale AC, Koech AC, Sheppard AE, et al. Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya. Nat Microbiol 2016;1:16067. https://doi.org/10.1038/nmicrobiol.2016.67
  57. Meehan M, Cunney R, Cafferkey M. Molecular epidemiology of group B streptococci in Ireland reveals a diverse population with evidence of capsular switching. Eur J Clin Microbiol Infect Dis 2014;33:1155-62. https://doi.org/10.1007/s10096-014-2055-5
  58. Ramaswamy SV, Ferrieri P, Flores AE, Paoletti LC. Molecular characterization of nontypeable group B streptococcus. J Clin Microbiol 2006;44:2398-403. https://doi.org/10.1128/JCM.02236-05

Cited by

  1. Progress toward a group B streptococcal vaccine vol.14, pp.11, 2018, https://doi.org/10.1080/21645515.2018.1493326
  2. Streptococcus agalactiae carriage among pregnant women living in Rio de Janeiro, Brazil, over a period of eight years vol.13, pp.5, 2018, https://doi.org/10.1371/journal.pone.0196925
  3. Perinatal Streptococcus agalactiae Epidemiology and Surveillance Targets vol.31, pp.4, 2018, https://doi.org/10.1128/cmr.00049-18
  4. Group B streptococcus prevalence, serotype distribution and colonization dynamics in Western Australian pregnant women vol.68, pp.5, 2019, https://doi.org/10.1099/jmm.0.000980
  5. Regioselective Glycosylation Strategies for the Synthesis of Group Ia and Ib Streptococcus Related Glycans Enable Elucidating Unique Conformations of the Capsular Polysaccharides vol.25, pp.71, 2019, https://doi.org/10.1002/chem.201903527
  6. The Epidemiology of Invasive Group B Streptococcus in Denmark From 2005 to 2018 vol.8, pp.None, 2018, https://doi.org/10.3389/fpubh.2020.00040
  7. Mucosal Vaccination with Lactococcus lactis -Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B Streptococcus in a Murine Model vol.8, pp.2, 2018, https://doi.org/10.3390/vaccines8020146
  8. Group B Streptococcus colonization rate and serotype distribution among pregnant women and their newborns at Adama Hospital Medical College, Ethiopia vol.10, pp.None, 2018, https://doi.org/10.1038/s41598-020-66474-z
  9. Impact of Intrapartum Antibiotic Prophylaxis on Offspring Microbiota vol.9, pp.None, 2021, https://doi.org/10.3389/fped.2021.754013
  10. A Narrative Review of the Molecular Epidemiology and Laboratory Surveillance of Vaccine Preventable Bacterial Meningitis Agents: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenza vol.9, pp.2, 2018, https://doi.org/10.3390/microorganisms9020449
  11. Capsular genotype distribution of Group B Streptococcus colonization among at-risk pregnant women in Sao Paulo, Brazil. vol.25, pp.3, 2018, https://doi.org/10.1016/j.bjid.2021.101586
  12. Group B streptococcal infections in infants in Iceland: clinical and microbiological factors vol.70, pp.9, 2018, https://doi.org/10.1099/jmm.0.001426
  13. Whole genome sequence based capsular typing and antimicrobial resistance prediction of Group B streptococcal isolates from colonized pregnant women in Nigeria vol.22, pp.1, 2021, https://doi.org/10.1186/s12864-021-07929-z
  14. Group B Streptococcal Colonization in African Countries: Prevalence, Capsular Serotypes, and Molecular Sequence Types vol.10, pp.12, 2018, https://doi.org/10.3390/pathogens10121606